17th Annual Gavin Herbert Eye Institute Colloquium

Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Allergan, an Abbvie Company

Seventy-five years ago, Gavin S. Herbert, Sr, and his son, Gavin Herbert, Jr, created Allergan, an AbbVie company, with the goal of improving the lives of patients. Since that time, Allergan has remained dedicated to advancing eye care, launching 125+ products for prevalent eye conditions. We are committed to helping Eye Care Providers deliver superior patient care through R&D, philanthropy, outreach programs, and support of academic institutions. © 2023 AbbVie. All rights reserved. All trademarks are the property of their respective owners. AllerganEyeCare.com US-ABBV-230085 04/23

Bausch + Lomb

Bausch + Lomb is a global eye health organization with core businesses in over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry.

Coherus BioSciences, Inc.

Coherus BioSciences, Inc. is committed to expanding patient access to cost-effective, lifesaving medicines and delivering significant savings to the U.S. healthcare system. Founded a decade ago with a focus on providing the highest quality biosimilar treatments, our team is deeply experienced in analytical and process sciences, clinical development, and regulatory affairs, with proven commercial capabilities. Building on our success with biosimilars, we are expanding our product portfolio to novel therapies.

Dompé

Dompé is an Italian biopharmaceutical company with a 130 year legacy of medical innovation. Based in Milan with US headquarters in the San Francisco Bay Area, Dompé is committed to medical and scientific advancements that address unmet medical needs in the areas of ophthalmology, transplants, oncology, and diabetes. To learn more about Dompé, email USMedinfo@dompe.com

Glaukos

Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders, and retinal diseases.

Iveric Bio, An Astellas Company

Iveric Bio, An Astellas Company Iveric (ivericbio.com) (609) 474-6755 8 Campus Drive, Parsippany-Troy Hills, NJ 07054 Iveric Bio, An Astellas Company, is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

Johnson & Johnson Vision

At Johnson & Johnson Vision, we have a bold ambition: to change the trajectory of eye health. Through our operating companies, we've developed solutions for every stage of life-to help people see better, connect better and live better. We partner with eye care professionals to provide some of the world's leading products and technologies to address refractive error, cataracts, dry eye, and beyond. We are committed to using our reach and size for good and strive to put quality eye care within reach of everyone, everywhere. Click the logo to watch a video.

New World Medical

At New World Medical, our mission is to preserve and enhance vision by delivering innovations to Benefit Humanity. Our innovations include the Ahmed® Family of Glaucoma Drainage Devices, the KDB GLIDE® and the STREAMLINE® Surgical System. NEW WORLD MEDICAL ~ HUMANITY’S VISION IS OUR FOCUS.

RxSight®

RxSight® is an ophthalmic medical technology corporation headquartered in Aliso Viejo, California that has commercialized the Light Adjustable Lens™ (LAL®), the world’s first and only adjustable intraocular lens (IOL) that is customized after cataract surgery. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye.

Sight Sciences

Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System technology is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. For more information, visit htp://www.sightsciences.com. OMNI and TearCare are registered trademarks of Sight Sciences. SION is a trademark of Sight Sciences. © 2023 Sight Sciences. All rights reserved.

STAAR

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 2,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, XDEMVEY, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. XDEMVEY is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial.